Table 4 DDX39B polymorphisms (-22C > G and -348C > T) and outcome of vivax malaria infections: first series of participants from Rondonia, Brazil

DDX39B-22 polymorphism

Uninfected (n = 77)

10 (12.99)

38 (49.35)

29 (37.66)

6.75 p = 0.1496

58 (37.66)

96 (62.34)

2.35 p = 0.3088

0.53 p = 0.7660

Asymptomatic malaria (n = 104)

15 (14.42)

64 (61.54)

25 (24.04)

94 (45.19)

114 (54.81)

Mild malaria (n =7 6)

13 (17.10)

34 (44.74)

29 (38.16)

60 (39.47)

92 (60.53)

Infected vs uninfected

1.48 p = 0.4758

p = 0.3281*

p = 0.2460*

Mild vs asymptomatic

2.90 p = 0.2339

p = 0.6244*

p = 0.7028*

Asymptomatic vs uninfected

3.98 p = 0.1364

p = 0.1625*

p = 0.8307*

Genotype

Allele frequency

CC vs TC + TT χ2

CC n (%)

TC n (%)

TT n (%)

C (%)

T (%)

DDX39B-348 polymorphism

Uninfected (n = 77)

64 (83.12)

12 (15.58)

1 (1.30)

1.99 p = 0.3691^#

140 (90.91)

14 (9.09)

1.00 p = 0.6041

1.56 p = 0.4586

Asymptomatic malaria (n = 104)

83 (79.81)

21 (20.19)

0 (0.00)

187 (89.90)

21 (10.10)

Mild malaria (n = 76)

57 (75.00)

19 (25.00)

0 (0.00)

133 (87.50)

19 (12.50)

Infected vs uninfected

p = 0.2397*^#

p = 0.5342*

p = 0.4012*

Symptomatic vs asymptomatic

p = 0.2372*^#

p = 0.3469*

p = 0.3108*

Asymptomatic vs uninfected

p = 0.5594*^#

p = 0.8578*

p = 0.7008*